M. Prévilon

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

D. Podzamczer, B. Clotet, A. Winston, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cardiac FKBP12.6 overexpression protects against triggered ventricular tachycardia in pressure overloaded mouse hearts

K. Sipido, F. Charpentier, S. Chimenti, 2012, Basic Research in Cardiology.

Sequential alterations in Akt, GSK3β, and calcineurin signalling in the mouse left ventricle after thoracic aortic constriction.

M. Pezet, P. Rouet-benzineb, J. Mercadier, 2010, Canadian journal of physiology and pharmacology.

Gender-Specific Potential Inhibitory Role of Ca2+/Calmodulin Dependent Protein Kinase Phosphatase (CaMKP) in Pressure-Overloaded Mouse Heart

M. Pezet, P. Rouet-benzineb, J. Mercadier, 2014, PloS one.

Comparative differential proteomic profiles of nonfailing and failing hearts after in vivo thoracic aortic constriction in mice overexpressing FKBP12.6

C. Broussard, P. Chafey, M. Pezet, 2013, Physiological reports.

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Andrew J. Oler, Eglantine Ferrand Devouge, P. Gregersen, 2023, Genome Medicine.

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

Andrew J. Oler, Eglantine Ferrand Devouge, P. Gregersen, 2023, Genome Medicine.

Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.

D. Podzamczer, B. Clotet, A. Winston, 2020, The Journal of antimicrobial chemotherapy.